Amgen Inc. (AMGN)
Biological Products, (No Diagnostic Substances) · market cap $219.9B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-11-30 (est.)Phase 2 · Anvumetostatimp 7/10
- 2026-12-14 (est.)Phase 3 · ABP 234imp 9/10
- 2026-12-30 (est.)Phase 2 · Blinatumomabimp 7/10
- 2027-01-06 (est.)Phase 2 · AMG 732imp 7/10
- 2027-01-15 (est.)Phase 2 · pegfilgrastimimp 7/10
- 2027-01-21 (est.)Phase 3 · Maridebart cafraglutideimp 9/10
- 2027-02-01 (est.)Phase 2 · Autologous Stem Cell Transplant (ASCT)imp 7/10
- 2027-03-15 (est.)Phase 2 · Romosozumab Prefilled Syringeimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) |
| Lumakras | Approved | KRAS G12C NSCLC |
| Tarlatamab | Phase 3 | Small Cell Lung Cancer |
| AMG 509 | Phase 1 | Prostate Cancer |
| Etanercept Liquid | Phase 3 | Rheumatoid Arthritis |
| Erenumab-aooe (EREN) s.c. administered every four weeks for a total of five treatments | Phase 2 | Temporomandibular Disorder |
| Vinblastine sulfate | Phase 2 | HIV Infections |
| PEG asparaginase | Phase 2 | Lymphoblastic Leukemia |
| romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis |
| bemarituzumab, trifluridine/tipiracil | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma |
| AMG 102 and erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Anvumetostat | Phase 2 | Advanced MTAP-null Solid Tumors |
| bemarituzumab, irinotecan | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma |
| Panitumumab + FOLFOX (DP) | Phase 2 | Metastatic Colorectal Cancer |
| Omitted Vincristine+Dexamethasone pulses | Phase 3 | Leukemia, Acute Lymphoblastic |
| Metoprolol | Phase 3 | Cardiovascular Disease |
| Inotuzumab Ozogamicin+Standard Maintenance Therapy | Phase 3 | Leukemia, Acute Lymphoblastic |
| Nitroglycerin | Phase 3 | Cardiovascular Disease |
| Evolocumab AI/pen | Phase 3 | Primary Hypercholesterolemia |
| 6-tioguanine+Standard Maintenance Therapy | Phase 3 | Leukemia, Acute Lymphoblastic |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for AMGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
